Asian Journal of Applied Science and Technology (AJAST)
Volume 5, Issue 3, Pages 149-155, July-September 2021

ARGIPUSH SYRUP ®: Therapeutic Benefits of L-Arginine for the Preeclampsia Complications

Dr. M. Sampoorna, Asst. Prof. Badugu Kranthi kumar, S.V. Bhavani & Asst. Prof. K. Jayasurya

Besiara Pharmaceuticals, Makers of ARGIPUSH ® Syrup, 4-77/2, Badangpet, Balapur (M), Hyderabad, Ranga Reddy Dist., Telangana-500058, India (www.besiara.com) Corresponding Author: Asst. Prof. K. Jayasurya

DOI: http://doi.org/10.38177/ajast.2021.5314

Article Received: 12 June 2021 *Article Accepted: 21 August 2021* *Article Published: 16 September 2021*

ABSTRACT

This study aims to assess the effectiveness of L-arginine for prevention of preeclampsia in high-risk pregnancy. Preeclampsia is a significant reason for maternal mortality and morbidity, preterm birth, perinatal demise, and intrauterine growth restriction. Preeclampsia is when women have hypertension and protein in urine during pregnancy or after delivery. And also having low coagulating factors (platelets) in blood or markers of kidney or liver problems. Proof demonstrates that endothelial dysfunction is key to the pathogenesis of preeclampsia. Arginine-nitric oxide pathway to assess endothelial dysfunction in normotensive pregnancies and pregnancies confounded with preeclampsia. Arginine assumes a critical part in proliferation, fetal development, support of tissue integrity, and immune function, and also the treatment of sicknesses in pregnancy. Maternal plasma arginine focuses were observed to be lower in pregnancies muddled by Intrauterine growth restriction (IUGR) and expands the fetal healthful enhancement.

Introduction

Preeclampsia is a significant reason for maternal mortality and morbidity, preterm birth, perinatal passing, and Intrauterine growth restriction (IUGR). Preeclampsia is when a woman has hypertension and perhaps protein in urine during pregnancy or after delivery. Likewise having a low level of platelets in blood or markers of kidney or liver problems. Preeclampsia occurs after the twentieth week of the pregnancy. Sometimes it happens prior, or after delivery. Eclampsia is a serious movement of preeclampsia. With this condition, hypertension brings about seizures. Like preeclampsia, eclampsia happens during pregnancy or, once in a while, after delivery. The l-arginine is a substrate for nitric oxide synthesis or production during pregnancy; According to the information proposes that supplemental l-arginine administration might bring down the danger of preeclampsia during pregnancy by advancing vasodilatation through creation of nitric oxide.

What is Preeclampsia?

Preeclampsia is if you have excessive blood pressure and having protein in your urine throughout pregnancy or after delivery. You may additionally have low clotting factors (platelets) in your blood or indicators of kidney or liver trouble. Preeclampsia usually occurs after the 20 th week of pregnancy. However, in a few instances it takes place earlier, or after delivery. Eclampsia is an intense development of preeclampsia. With this condition, excessive blood pressure effects seizures. Like preeclampsia, eclampsia happens during pregnancy or, rarely, after delivery.

Causes

- Autoimmune disorders
- Being obese
- Having a history of high blood pressure
- Having a history of diabetes

- Having a history of a kidney disorder
- Being pregnant with multiple fetuses
- Being over the age of 35
- Genetic factors
- blood vessel problems
- Being in your early teens
- Being pregnant for the first time

Symptoms of Preeclampsia

- Persistent headache
- Abnormal swelling in your hands and face
- Sudden weight gain
- Changes in your vision
- Pain in the right upper abdomen

The doctor examined blood pressure is 140/90 mm Hg or higher. Urine examination and blood tests can also show protein in the urine, abnormal liver enzymes components, and a low level of the platelet.

Complications of preeclampsia

Preeclampsia is in exceptional condition. It will in general be dangerous for both mother and baby at whatever point left untreated. Various hardships can include:

- Hemorrhage due to low platelet levels
- Kidney failure
- Pulmonary oedema
- Complications for the child can also happen in case they're conceived too early because of efforts to resolve problems of preeclampsia
- Placental abruption (breaking away of the placenta from the uterine wall)
- Damage to the liver

Pathophysiology of Preeclampsia

During implantation, placental trophoblasts attack the uterus and happen to redesign, while devastating the tunica media of the myometrial winding supply routes; this permits the arteries to oblige expanded bloodstream free of maternal vasomotor changes to support the creating fetus. Some portion of this redesigning necessitates that the trophoblasts embrace an endothelial aggregate and its different molecules. if any chance this rebuilding or remodeling is hindered, the placenta is probably going to be denied of oxygen, which prompts a condition of relative ischemia and an increase in oxidative pressure during conditions of discontinuous perfusion. This strange

twisting supply was seen and portrayed more than fifty years prior in pregnant ladies who were hypertensive. It has since been demonstrated to be the central pathogenic factor in pregnancies complicated by intrauterine development limitation or intrauterine growth restrictions, gestational hypertension, and preeclampsia. One constraint to this hypothesis, subsequently, is that these discoveries are not explicit to preeclampsia and may clarify the distinction in appearances between placental preeclampsia and maternal preeclampsia.



***Objective**:* This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.

L-Arginine Profile

Arginine, and also called l-arginine (Arg or R) is an α-amino acid that is utilized in the biosynthesis of proteins. L-arginine is converted in the body into a substance called nitric oxide. Nitric oxide causes blood vessels to open more extensively for further developed blood flow. L-arginine additionally stimulates the release of hormones and other different substances in the body [5].

Arginine has a significant part in cell division, wound healing, eliminating ammonia from the body, immunity development, and the release of hormones. Significant role in regulating the blood pressure.

Mechanism of Action

Normal being pregnant results in profound maternal hemodynamic changes, which include elevated blood extent and vasodilatation. Several vasodilator mediators are implicated, which include prostaglandins, carbon monoxide and nitric oxide (NO). Pre-eclampsia (PE) influences 3–10 % of pregnancies and is related to accelerated maternal and perinatal morbidity and mortality. Around 8 % of pregnancies are complex via way of means of intra-uterine

growth restriction (IUGR), additionally related to accelerated perinatal mortality and morbidity. PE and IUGR frequently co-exist.

NO is crucial for the formation of healthy endothelium, and in being pregnant promotes endovascular invasion via way of means of the cytotrophoblast. As interstitial trophoblasts invade the maternal spiral arteries withinside the uterine wall, they produce NO which acts on artery partitions to create a low-resistance, high-quality uteroplacental unit. If this method fails, the end result is a high-resistance uteroplacental circulation. The hypo perfused and ischemic placenta releases antiangiogenic elements which mediate generalized endothelial dysfunction, oxidative stress and inflammatory mediators.

It is those mediators which can be implicated in each the fetal and maternal syndromes of PE and IUGR. Studies of NO and its modulator amino acids, consisting of the precursors arginine and homoarginine and the NO synthesis inhibitor asymmetric dimethylarginine (ADMA), have investigated their function in each regular and pathological pregnancies. Many researches of PE (and, to a lesser extent, IUGR) have investigated maternal circulating ADMA, arginine and homoarginine levels. This article evaluations and discusses the position of those amino acids in pregnancy. The consequences have shed a few mild on their position in those pathologies, however a number of the findings had been conflicting and extra studies is needed [3].



Literature Review

Heldayanti Sirenden, et al., (2019): Objective: The purpose of this was to look at serum levels of l-arginine in ordinary pregnant ladies, serious preeclampsia, and extreme preeclampsia with complications. **Methods:** This was an observational investigation with a cross-sectional plan, 88 third trimester of pregnancy turned into the example which comprised of 46 ordinary pregnant ladies, 30 serious preeclampsia, and 12 extreme preeclampsia with complexity. This study has been conducted in four medical clinics in the city of Makassar: Dr. Wahidin Sudirohusodo medical clinic, training Hospital of Hasanuddin University, Fatimah, and Sitti Khadijah 1 Mothers

and Children medical clinic. Serum blood tests has been taken from the antecubital venous blood Assessment of serum l-arginine levels was completed utilizing the Human l-Arginine Assay Kit. **Results:** There were huge mean differences between typical, extreme pre-eclampsia with complications. The most minimal serum levels of l-arginine were extreme preeclampsia with complications (28.33ng/mL), then, at that point serious preeclampsia bunch (34.66ng/mL), and the most elevated was typical pregnant women (60.91ng/mL). Conclusion: Severe preeclampsia with complications had the most low level of l-arginine. Function of l-arginine level ought to be considered in the prevention and treatment of extreme preeclampsia. **Conclusion:** L-arginine (Argipush ®) management is promising in develops quantity of amniotic fluid in instances of oligohydramnios. L-Arginine performs a essential role in reproduction, fetal development, protection of tissue integrity, and immune function, in addition to remedy of illnesses in pregnancy. Maternal plasma arginine concentrations have been observed to be decrease in pregnancies complex through IUGR and will increase the fetal dietary supplements.

Background: Pre-eclampsia is a significant reason for maternal and neonatal morbidity and mortality in sub-Saharan Africa. Proof shows that endothelial dysfunction is fundamental to the pathogenesis of preeclampsia. This examination surveyed the level of the parts of the arginine-nitric oxide pathway to assess endothelial dysfunction in normotensive pregnancies and pregnancies complications with preeclampsia. **Methods:** This case-control study was directed among pregnant ladies who visited Comboni Hospital from January 2017 to May 2018. An aggregate of 180 pregnant ladies containing 88 preeclamptic ladies (PE) and 92 sound normotensive pregnant ladies (NP) were selected. Sociodemographic, clinical, and obstetric information were acquired utilizing approved surveys. Circulatory strain and anthropometrics were estimated, and blood tests were gathered for the assessment of nitric oxide (NO·), L-arginine, lopsided dimethylarginine (ADMA), and 3-nitrotyrosine utilizing a chemical connected immunosorbent measure strategy. **Results:** The mean NO· ($p = 0.010$) and L-arginine/ADMA proportion ($p < 0.0001$) was altogether lower in PE contrasted with NP while mean L-arginine ($p = 0.034$), ADMA ($p < 0.0001$), and 3-nitrotyrosine ($p < 0.0001$) were essentially higher in PE than NP. ADMA showed a critical positive relationship with systolic pulse ($\beta = 0.454$, $p = 0.036$) in extreme PE. Ladies with PE had huge intrauterine development limitation ($p < 0.0001$) and low birth weight newborn children ($p < 0.0001$) when contrasted with NP. **Conclusion:** Preeclampsia is related with diminished NO· bioavailability, L-arginine/ADMA proportion, and raised degrees of ADMA and 3-nitrotyrosine. Estimations of the levels of these boundaries can help in the early expectation of endothelial dysfunction in preeclampsia. Exogenous helpful supplementation with L-arginine during pregnancy to expand the L-arginine/ADMA proportion ought to be considered to work on endothelial capacity in preeclampsia and pregnant women in danger of creating preeclampsia.

Objective: This assessment is to be observe the L-arginine for preventing pre-eclampsia in high-risk pregnancy. **Methods:** We did a randomized, double-blind, placebo-controlled, clinical preliminary trail in patients with high-risk preeclampsia. Fifty subjects got L-arginine, starting from the 20th week of gestation. An extra 50 patients got homologated placebo treatment. **Results:** The placebo group had a more of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight also higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03). Conclusion: L-arginine is more worthful for preventing preeclampsia. **Conclusion:** L-arginine (Argipush ®) administration is promising in develops volume of amniotic

fluid in cases of oligohydramnios. L-Arginine plays a crucial role in reproduction, fetal development, maintenance of tissue integrity, and immune function, as well as treatment of diseases in pregnancy. Maternal plasma arginine concentrations were found to be lower in pregnancies complicated by intrauterine growth retardation (IUGR) and increases the fetal nutritional supplements.

Declarations

Source of Funding

This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing Interests Statement

The authors declare no competing financial, professional and personal interests.

Consent for publication

Authors declare that they consented for the publication of this research work.

References

1. Jennifer Uzan, Marie Carbonnel, Olivier Piconne, Pre-eclampsia: pathophysiology, diagnosis, and management, Vasc Health Risk Manag., 7: 467-474, 2011, DOI: 10.2147/VHRM.S20181.

2. E Camarena Pulido, L García Benavides, J G Panduro Barón, Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial, Hypertens Pregnancy, 35(2): 217-25, 2016, DOI: 10.3109/10641955.2015.1137586.

3. C. V. Hegde The Use of l-Arginine in the Management of Pre-Eclampsia and Intrauterine Growth Restriction, J Obstet Gynaecol India, 62(1): 1-2, 2012, DOI: 10.1007/s13224-012-0146-8.

4. Elizabeth Phipps, Devika Prasanna, Wunnie Brima and Belinda Jim, Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines, CJASN, 11(6): 1102-1113, 2016, DOI: 10.2215/CJN.12081115.

5. Nomenclature and Symbolism for Amino Acids and Peptides, IUPAC-IUB Joint Commission on Biochemical Nomenclature, 1983, Archived from the original on 9 October 2008, Retrieved 5 March 2018.

6. Mauro C, Frezza C (2015-07-13), The Metabolic Challenges of Immune Cells in Health and Disease, Frontiers Media SA., pp.17, ISBN: 9782889196227.

7. Tapiero H, Mathé G, Couvreur P, Tew KD (November 2002). "L-Arginine", (review), Biomedicine & Pharmacotherapy, 56(9): 439-445, DOI: 10.1016/s0753-3322(02)00284-6, PMID 12481980.

8. Stechmiller JK, Childress B, Cowan L (February 2005). Arginine supplementation and wound healing, (review), Nutrition in Clinical Practice, 20(1): 52-61, DOI: 10.1177/011542650502000152, PMID 16207646.

9. Witte MB, Barbul A., Arginine physiology and its implication for wound healing, (review), Wound Repair and Regeneration, 11(6): 419-23, 2003, DOI: 10.1046/j.1524-475X.2003.11605.x, PMID 14617280.

10. Andrew PJ, Mayer B., Enzymatic function of nitric oxide synthases, (review), Cardiovascular Research, 43(3): 521-31, 1999, DOI: 10.1016/S0008-6363(99)00115-7, PMID 10690324.

11. Morris N, Eaton BM., Nitric oxide, the endothelium, pregnancy and pre-eclampsia, Br. J. Obstet. Gynaecol., 103: 4-15, 1996, DOI: 10.1111/j.1471-0528.1996.tb09508.x.

12. Savvidou MD, Hingorani AD, Tsikas D, et al., Endothelial dysfunction and raised plasma concentrations of asymmetric dimetylarginine in pregnant women who subsequently develop pre-eclampsia, Lancet, 361: 1511-1517, 2003, DOI: 10.1016/S0140-6736(03)13177-7.

13. Venkatesha S, Toporsian M, Lam C, et al., Soluble endoglin contributes to the pathogenesis of pre-eclampsia, Nat Med., 12: 642-649, 2006, DOI: 10.1038/nm1429.

14. Meher S, Duley L., Nitric oxide for preventing pre-eclampsia and its complications, Cochrane Database Syst Rev., 2, 2007, CD006490.

15. Hishikawa K, Nakaki T, Tsuda M, et al., Effects of systemic l-arginine administration on hemodynamics and nitric oxide release in man, Jpn Heart J., 33: 41-48, 1992, DOI: 10.1536/ihj.33.41.

16. Campese VM, Amar M, Anjali C, et al., Effects of l-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension, J. Hum. Hypertens., 11: 527-532, 1997, DOI: 10.1038/sj.jhh. 1000485.

17. A. Khalil, L. Hardman, Pat O´Brien, The role of arginine, homoarginine and nitric oxide in pregnancy, DOI: 10. 1007/s00726-015-2014-1, Corpus ID: 18426437.

18. Chien-Ning Hsu and You-Lin Tain, Impact of Arginine Nutrition and Metabolism during Pregnancy on Offspring Outcomes, Nutrients, 11(7): 1452, 2019, DOI: 10.3390/nu11071452.